Tissue analytics start-up 3scan has filed a form D with the Securities and Exchange Commission to issue $14 million in new securities. Proceeds from the sale are being used to enhance their automated pathology system and increase their market presence.
“Our immediate goal is to improve our software platform and expand our place in the pre-clinical drug discovery market,” noted COO and co-founder Megan Klimen.
To get a read on diseased tissue, pathologists and researchers manually cut thin slices and then stain and analyze them under a microscope – much as their predecessors have done for more than 150 years.
Read Full Article »